Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

244 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Defining the Position of [177Lu]Lu-PSMA Radioligand Therapy in the Treatment Landscape of Metastatic Castration-Resistant Prostate Cancer: A Meta-analysis of Clinical Trials.
Ciccarese C, Bauckneht M, Zagaria L, Fornarini G, Beccia V, Lanfranchi F, Perotti G, Pinterpe G, Migliaccio F, Tortora G, Leccisotti L, Sambuceti G, Giordano A, Caffo O, Iacovelli R. Ciccarese C, et al. Among authors: iacovelli r. Target Oncol. 2024 Nov 29. doi: 10.1007/s11523-024-01117-1. Online ahead of print. Target Oncol. 2024. PMID: 39613950
Second-line therapy for metastatic urothelial carcinoma: Defining the best treatment option among immunotherapy, chemotherapy, and antiangiogenic targeted therapies. A systematic review and meta-analysis.
Ciccarese C, Iacovelli R, Bria E, Mosillo C, Bimbatti D, Fantinel E, Bisogno I, Brunelli M, Tortora G. Ciccarese C, et al. Among authors: iacovelli r. Semin Oncol. 2019 Feb;46(1):65-72. doi: 10.1053/j.seminoncol.2019.01.001. Epub 2019 Jan 14. Semin Oncol. 2019. PMID: 30665685
Going towards a precise definition of the therapeutic management of de-novo metastatic castration sensitive prostate cancer patients: How prognostic classification impact treatment decisions.
Iacovelli R, Ciccarese C, Schinzari G, Maiorano BA, Rossi E, Pierconti F, Bassi PF, Bria E, Tortora G. Iacovelli R, et al. Crit Rev Oncol Hematol. 2019 Jul;139:83-86. doi: 10.1016/j.critrevonc.2019.05.005. Epub 2019 May 11. Crit Rev Oncol Hematol. 2019. PMID: 31112886 Review.
The prognostic value of pain in castration-sensitive prostate cancer.
Iacovelli R, Ciccarese C, Caffo O, De Giorgi U, Tucci M, Mosillo C, Bimbatti D, Pierantoni F, Maines F, Casadei C, Buttigliero C, Milella M, Tortora G. Iacovelli R, et al. Prostate Cancer Prostatic Dis. 2020 Dec;23(4):654-660. doi: 10.1038/s41391-020-0255-x. Epub 2020 Jul 10. Prostate Cancer Prostatic Dis. 2020. PMID: 32651468
Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis.
Iacovelli R, Ciccarese C, Facchini G, Milella M, Urbano F, Basso U, De Giorgi U, Sabbatini R, Santini D, Berardi R, Santoni M, Bracarda S, Massari F, Masini C, De Tursi M, Ricotta R, Buti S, Zustovich F, Sepe P, Rossetti S, Maruzzo M, Cortesi E, Tortora G, Procopio G. Iacovelli R, et al. Target Oncol. 2020 Aug;15(4):495-501. doi: 10.1007/s11523-020-00732-y. Target Oncol. 2020. PMID: 32671807
244 results